Table 3.

Markers with significant change over time (n = 15) in HCT-treated patients with MPS I

MarkerSlope*PPathwayDifferentiating pre-HCT
CXCL9 −0.09 .049 Pro-inflammatory Yes 
CXCL10 −0.12 .04 Pro-inflammatory No 
CCL3 −0.13 .01 Pro-inflammatory No 
CCL4 −0.10 .02 Pro-inflammatory Yes 
CCL19 −0.09 .03 Pro-inflammatory No 
CCL20 −0.09 .04 Pro-inflammatory No 
CCL25 −0.08 .02 Pro-inflammatory No 
MCP.3 −0.07 .03 Pro-inflammatory No 
IFN.γ −0.12 .04 Pro-inflammatory No 
TNF −0.07 .009 Pro-inflammatory No 
TNFB −0.06 .04 Pro-inflammatory No 
TNFRSF9 −0.08 .009 Pro-inflammatory No 
CDCP1 −0.06 .04 Pro-inflammatory No 
Flt3L 0.1 .03 Growth factor/bone homeostasis No 
SCF 0.1 .03 Growth factor/bone homeostasis Yes 
MarkerSlope*PPathwayDifferentiating pre-HCT
CXCL9 −0.09 .049 Pro-inflammatory Yes 
CXCL10 −0.12 .04 Pro-inflammatory No 
CCL3 −0.13 .01 Pro-inflammatory No 
CCL4 −0.10 .02 Pro-inflammatory Yes 
CCL19 −0.09 .03 Pro-inflammatory No 
CCL20 −0.09 .04 Pro-inflammatory No 
CCL25 −0.08 .02 Pro-inflammatory No 
MCP.3 −0.07 .03 Pro-inflammatory No 
IFN.γ −0.12 .04 Pro-inflammatory No 
TNF −0.07 .009 Pro-inflammatory No 
TNFB −0.06 .04 Pro-inflammatory No 
TNFRSF9 −0.08 .009 Pro-inflammatory No 
CDCP1 −0.06 .04 Pro-inflammatory No 
Flt3L 0.1 .03 Growth factor/bone homeostasis No 
SCF 0.1 .03 Growth factor/bone homeostasis Yes 

CCL, C-C motif chemokine ligand; CXCL, C-C-C motif chemokine ligand; IFN, interferon; MCP, monocyte chemoattractant protein; SCF, stem cell factor; TNF-a, tumor necrosis factor alpha; TNFRSF, tumor necrosis factor receptor superfamily

*

The slope of the linear mixed model indicates the change in NPX unit per year.

Close Modal

or Create an Account

Close Modal
Close Modal